China approves AstraZeneca’s Symbicort Turbuhaler for asthma
AstraZeneca has secured China’s National Medical Products Administration (NMPA) approval for its anti-inflammatory reliever Symbicort Turbuhaler (budesonide/formoterol 160/4.5mcg) to control symptoms of asthma in patients aged 12 years